Academy Professor Seppo Ylä-Herttuala is a pioneer and international leader in cardiovascular gene therapy. He was the first in the world to apply adenoviral gene transfer to human arteries in 1995. Since then he has developed both gene transfer vectors and production systems and a highly successful research team focusing on angiogenesis, VEGF biology and its clinical applications.
研究方向
Virus-based gene therapy researchAngiogenesis and VEGF in CancerAtherosclerosis and Cardiovascular DiseasesRNA Interference and Gene DeliveryLymphatic System and Diseases
